Navigation Links
Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
Date:10/2/2007

ISIS 325568 is an Antisense Drug Targeting Glucagon Receptor for Treatment

of Type 2 Diabetes

CARLSBAD, Calif., Oct. 2 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today it has earned $5 million from Ortho-McNeil, Inc. (OMI), a Johnson & Johnson company, for achieving the first development milestone of initializing the Phase 1 clinical trial of ISIS 325568.

The collaboration between Isis and OMI, announced on September 13, 2007, includes the licensing of two second-generation antisense drugs, ISIS 325568 and ISIS 377131, both of which represent novel approaches for the treatment of metabolic disease. ISIS 325568 was designed to selectively inhibit the production of glucagon receptor and has demonstrated improved glucose control in animal models of Type 2 diabetes.

"We are pleased to have achieved this milestone so early in our collaboration with Ortho-McNeil, Inc.," said Jeffrey Jonas, M.D., Executive Vice President, Isis Pharmaceuticals. "OMI will be providing all funding for this study, while Isis will be managing the study through to completion before handing all additional development responsibilities over to our partner."

ABOUT GLUCAGON RECEPTOR (GCGR), TARGET OF ISIS 325568

Glucagon is a hormone that opposes the action of insulin and stimulates the liver to produce glucose. In Type 2 diabetes, unopposed action of glucagon can lead to increased blood glucose levels. Reducing the expression of liver GCGR using antisense inhibitors, and thereby reducing excessive liver glucose production, is expected to lower blood glucose levels and help control Type 2 diabetes. In preclinical studies, antisense inhibitors of GCGR led to im
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pelosi: Bush Veto of Stem Cell Bill Says No to the Hopes of Million of Families Across America
2. Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million Annually
3. MIV Therapeutics Announces Renowned Researcher to Detail Milestone Pre-Clinical Results at Prominent International Conference EuroPCR 2007
4. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
5. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
6. Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  The U.S. Department of Health and ... University Hospitals (UH) Case Medical Center Seidman Cancer Center ... aimed at improving care for patients with complex cancer. ... will test a unique model developed at UH to ... significant comorbidities, or demonstrated need for high health care ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
(Date:7/10/2014)... 2014 Yesterday, former Congressman Patrick ... manufacturing facility. Rep. Kennedy and Dick Moberg ... cutting-edge research in neurological disease and treatment. ... advocate, Garen Staglin , created One Mind, ... changes that will radically accelerate the development and ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2
... Greenville, SC, announced today that its Glucommander™ 2.0 Enterprise software ... 2 - 17. Glytec,s Glucommander was the first insulin dosing ... it is the only company to achieve specific ... company cleared to offer this technology to hospitals caring for ...
... OLATHE, Kan., May 21, 2012  BD (Becton, Dickinson and ... medical technology company, and Heart to Heart International, a ... their second joint volunteer initiative to strengthen healthcare in ... the world will build upon the progress made by ...
Cached Medicine Technology:Glytec Adds Pediatric Insulin Dosing to its IV and SubQ FDA Clearances 2BD and Heart to Heart International Collaborate on Second Volunteer Service Trip to Help Improve Healthcare in Haiti 2BD and Heart to Heart International Collaborate on Second Volunteer Service Trip to Help Improve Healthcare in Haiti 3
(Date:7/12/2014)... Using and carrying around a catheter ... from Ashland, Va., decided that there needed to be ... to conceive of our design," he said. , They ... which provides an inconspicuous way to use and carry ... as promotes comfort and peace of mind. Producible in ...
(Date:7/12/2014)... July 12, 2014 For those who are ... can readily absorb the nutrients in food. The enzymes literally ... are small enough to be absorbed by human bodies. According ... lack of enzymes in regular food is the cause of ... that was started by Michelle DelPresto, a mother of 3 ...
(Date:7/12/2014)... 2014 Doylestown Hospital recently conducted an ... men’s health questions. Paddock tackles topics including main ... women live longer than men, and testosterone replacement therapy, ... Simple featured on Doylestown Hospital’s website, Dr. Brad ... any age. If you notice pain, bulging, or asymmetry ...
(Date:7/12/2014)... Emirates (PRWEB) July 12, 2014 Dubai ... Angeles basketball legend is heading to the UAE. ... six-time champion will be in the UAE from 28-31 ... Weekend in support of diabetes awareness. The event is ... entertainment marketing and event management company based in Dubai. ...
(Date:7/12/2014)... 2014 Wright & Schulte LLC, an experienced ... For Men Lawsuits (case #59776/2014), announces they have launched ... that allege the popular hair dye, Just For Men, has ... face, neck and other areas. In addition to detailing symptoms ... burns , the advertisements being run by Wright & Schulte ...
Breaking Medicine News(10 mins):Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 4
... An international team led by MUHC has identified the ... common congenital blindness in infants and small children. The ... and is partly funded by the Foundation Fighting Blindness in ... fast-track a cure for this disease, says lead investigator Dr. ...
... in the June 6 issue of JAMA, has identified ... It states that these mutations are due to ... has been released early to coincide with its presentation ... Clinical Oncology. ,According to background information in ...
... study published in the journal Health Psychology, by the ... a short temper or mean disposition tend to ... asthma and smoking were ruled out as possible causes ... 4,629 Black and White 18-30 year olds from four ...
... follow-up of National Surgical Adjuvant Breast and Bowel Project ... the American Society of Clinical Oncology (ASCO) in ... in women treated with trastuzumab (Herceptin) and combination chemotherapy ... ,The research team developed a prediction model ...
... presented today at the American Society of Clinical Oncology ... oncologist, reveals that a novel application of the drug ... multiforme. The study was conducted by North Central Cancer ... Rochester, Minn. Eva is the lead investigator of the ...
... care, emergency service and intensive care units at the Escorts ... its new owner Fortis Healthcare. ,"We will ... Fortis Healthcare managing director Shivinder Mohan Singh said Monday. ... project, the hospital was not getting the desired focus for ...
Cached Medicine News:Health News:Gene Responsible for Blindness in Infants and Children Identified 2Health News:Researchers Identify Genetic Mutations for Hereditary Diffuse Gastric Cancer 2Health News:Researchers Identify Genetic Mutations for Hereditary Diffuse Gastric Cancer 3Health News:Unhealthy Lungs Linked to Hostility? 2Health News:Long-term Use of Herceptin Does Not Increase Heart Failure in Patients 2Health News:Recurrent Gliomas: Vorinostat Shows Anti-cancer Activity 2Health News:Fortis to Inject Rs.300 Mn into Escorts Hospital 2
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
... The CSV-1000RS test face is used ... test presents ETDRS LogMAR acuity from 20/10 ... frequency at 12 cycles/degree. , ,The patient ... chair for ETDRS acuity and contrast sensitivity. ...
The first book to translate key medical data into clear guidelines capturing the highest treatment standards for heart disease....
... all those involved with healthcare decisions to ... latest evidence in their field of interest ... year as the volume of evidence increases. ... the best single source available for continually ...
Medicine Products: